Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-15
2008-07-15
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S186000, C546S188000
Reexamination Certificate
active
07399771
ABSTRACT:
Disclosed are compounds of formula I:wherein R1, R2, R3and X are as defined herein, in free or salt form, which are useful as CCR5 inhibitors, e.g. in the prevention or treatment of disorders mediated by interactions between chemokine receptors and their ligands.
REFERENCES:
patent: 2004/0142920 (2004-07-01), Albert et al.
patent: WO9801425 (1998-01-01), None
patent: 00/66559 (2000-11-01), None
patent: WO0066559 (2000-11-01), None
patent: 02/081449 (2002-10-01), None
patent: WO02081449 (2002-10-01), None
patent: 03/020716 (2003-03-01), None
: http://www.bakerbotts.com/infocenter/publications/detail.aspx?id=bffe4a7d-5beb-4cf8-a189-15a5f190f0eb).
http://www.dorsey.com/publications/legal—detail.aspx?FlashNavID=pubs—legal&pubid=170565003).
Cohen et al., Am. J. Clin. Pathol., 1996, 105, 589.
Assigment WO 02/081449, U.S. Appl. No. 10/472,653.
Thom et al. “Orally bioavailable . . . ” J. Med. Chem. 47, p. 1939-55 (2004).
Jewell et al. “Susceptibility . . . ” CA 134:250801 (2001).
Youhua et al. “Clinical study of . . . ” Transplatation Proceedings v.32 p. 1704 (2000).
Palani et al., “Discovery of 4-[(Z)-(4-Bromophenyl)-(ethoxyimino)methyl]-1′-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4′-methyl-1,4′-bipiperidine N-Oxide (SCH 351125): An Orally Bioavailable Human CCR5 Antagonist for the treatment of HIV Infection”, J. Med. Chem., vol. 44, No. 21, pp. 3339-3342 (2001).
Albert Rainer
Bruns Christian
Cooke Nigel Graham
Nuninger François
Streiff Markus
Chang Celia
Novartis AG
Novartis AG
LandOfFree
Piperidine derivatives as CCR5 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidine derivatives as CCR5 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine derivatives as CCR5 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2797327